CXL Ophthalmics is developing a minimally-invasive treatment for ectatic corneal disease that can bring early intervention to millions of patients globally. Their EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without disrupting the epithelium, allowing for a rapid return to normal activities.